Zydus Lifesciences Division Zylidac Bio Partners to Scale Prolific Machines Technology

Key numbers

Market Cap	₹1,12,426.52 CrLarge Cap
P/E TTM	24.91Sector PE 44.82
Revenue Growth	21.96%YoY Quarterly
Promoter Holding	75.01%No pledge

Key highlights

• Partnership scales optogenetics-enabled cell line development for complex biologics
• Prolific reported a record productivity milestone of 21 g/L for monoclonal antibodies
• Initial tech transfer will commence at a 50-liter scale at Zylidac's Emeryville facility
• Zydus reported Q1 FY27 operating revenue of ₹8,017 Crore, a 22 percent YoY increase
• Technology allows light-controlled protein expression in existing standard bioreactors

Scaling Optogenetics in Biologics Manufacturing

Zylidac Bio and Prolific Machines are collaborating to transition a proprietary light-controlled cell line platform into the GMP manufacturing environment. Prolific's technology utilizes light to regulate protein expression in engineered cell lines, which has demonstrated substantial improvements in productivity and product quality. The platform has achieved a milestone of 21 g/L in a 15-day intensified fed-batch run for monoclonal antibodies at small scale.

This partnership specifically targets the production of difficult-to-express proteins, including multi-specific antibodies, fusion proteins, and cytokines, using AI-driven process optimization and advanced analytics integrated into standard bioreactor systems.

Operational Roadmap at the Emeryville Facility

• Tech transfer begins at a 50-liter scale to reproduce development-level results
• Planned scaling of client programs to 250 liters before entering full GMP production
• Integration of Prolific illumination hardware into Zylidac's existing infrastructure
• Utilization of Zylidac's 83,000-square-foot facility for end-to-end manufacturing
• Pathway covers drug substance, drug product manufacturing, and fill-finish services

Accelerating the Biologics Pipeline

After demonstrating success at development scale with industry-leading yields across mAbs and difficult-to-express proteins, the next step is scaling the technology to GMP production for clinical and commercial supply.

Zydus Corporate Context and Strategic Alliances

The partnership follows a series of strategic moves by Zydus Lifesciences to expand its global biologics and pharmaceutical footprint. In June 2026, the company formed a 50:50 joint venture with Sunshine Healthcare Lanka to establish a manufacturing plant in Sri Lanka. Zydus also secured exclusive licensing deals in late 2025 with Bioeq AG and Formycon AG for biosimilars targeting the US and Canadian markets.

For the quarter ended June 30, 2026, Zydus reported a net profit of ₹939.8 Crore on revenue of ₹8,017 Crore, maintaining an operating profit margin of 24.1 percent.

What to watch next

• Board meeting scheduled for November 04, 2026, to approve Q2 FY27 financial results
• US FDA substantive review decision on Keytruda biosimilar FYB206 expected in Q3 2027
• Completion of 50-liter scale tech transfer at the Emeryville site
• Targeted commencement of commercial operations at Sri Lanka facility in 2028

“Prolific focuses on early-stage cell line development work, while we offer the process development, scale-up and GMP capacity required for later stages, including programs based on new expression technology like Prolific's.”

Zydus Lifesciences · financial snapshot

Share price	₹1117.3
Market capitalisation	₹1.12L Cr
Revenue (annual)	₹27,148.40 Cr
Net profit (annual)	₹5,040.00 Cr
Revenue (latest quarter)	₹8,017.00 Cr+5.67% vs previous quarter
Net profit (latest quarter)	₹939.80 Cr-26.15% vs previous quarter
P/E (TTM)	24.91×Sector 44.82×
Promoter holding	75.01%0.00% QoQ
FII holding	7.05%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.